Coagulation Factor III 靶点蛋白|抗体药物|临床药物信息

Coagulation Factor III信息

英文名称：Tissue factor
中文名称：组织因子
靶点别称：Coagulation Factor III (Thromboplastin， Tissue Factor)，Thromboplastin，Coagulation Factor III， Tissue Factor，TFA，F3，TF，CD142 Antigen，CD142，Coagulation Factor III，Tissue Factor

上市药物数量：1
临床药物数量：3
最高研发阶段：批准上市

Coagulation Factor III产品列表

筛选结果

产品库

在线 (4)

物种

标签

属性

Protein (4)

标记

Unconjugated (4)

货号	物种	产品描述
TF3-H52H5	Human	Human Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified)
TF3-H5253	Human	Human Coagulation Factor III / Tissue Factor Protein, Fc Tag (active enzyme)
TF3-M52H3	Mouse	Mouse Coagulation Factor III / Tissue Factor Protein, His Tag (MALS verified)
TF3-C52H3	Cynomolgus	Cynomolgus Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified)

Coagulation Factor III 分子别名

Coagulation Factor III,Tissue Factor,TF,F3,CD142

Coagulation Factor III 分子背景

Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Coagulation Factor III 前沿进展

Coagulation Factor III上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Tisotumab vedotin		TF-011-MMAE	批准上市	Genmab A/S	HuMax-TF, TIVDAK	United States	宫颈癌	Seagen Inc	2021-09-20	卵巢癌, 实体瘤, 食道癌, 头颈部鳞状细胞癌, 胰腺癌, 膀胱癌, 前列腺癌, 腹膜癌, 结直肠癌, 子宫内膜癌, 输卵管癌, 宫颈癌, 非小细胞肺癌	详情

Coagulation Factor III临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
Recombinant NAPc2	AB-201	临床三期	Dendreon Uk Ltd	新型冠状病毒肺炎	详情
XB-002	ICON-2; XB-002	临床一期	Iconic Therapeutics Inc	实体瘤, 头颈部鳞状细胞癌, 转移性上皮癌, 三阴性乳腺癌, 胰腺癌, 卵巢上皮癌, 去势抵抗性前列腺肿瘤, 乳腺癌, 前列腺癌, 食管鳞状细胞癌, 泌尿生殖道肿瘤, 非小细胞肺癌, 宫颈癌	详情
MRG004A	MRG004A	临床二期	上海美雅珂生物技术有限责任公司	实体瘤	详情

会议日历

会议一览

Coagulation Factor III